This website provides information about the business field of CO.DON GmbH, which has taken over the business operations from CO.DON AG.
Information on CO.DON Aktiengesellschaft can be found at

CO.DON: Treatment of patients starts in Switzerland

Berlin / Teltow / Leipzig, 07 September 2020 – The Inselspital in Bern, Bern’s university hospital, has become the first Swiss clinic to start treating patients with the 100% autologous chondrocyte transplant Spherox. The Inselspital is one of the biggest healthcare centres in Switzerland. It collaborates with the Medical Faculty of Bern University for both teaching and research.

Prof. Dr. med. Dr. phil. nat. Frank M. Klenke, Consultant and Team Leader for Knee and Sport Orthopaedics at the University Hospital for Orthopaedic Surgery and Traumatology at the Inselspital in Bern: “I am delighted that the certification of our clinic was so quick and straightforward. It meant that today we were able to perform the first operation in Switzerland to remove cartilage cells.”

Tilmann Bur, Executive Board of CO.DON AG: “We are entering the market earlier than originally planned, thanks to our good and constructive working relationship with the relevant Swiss authorities and customers. We are treating patients outside the EU framework for the first time, which represents another milestone in the implementation of our international business strategy. With the Inselspital we have acquired a partner of renown for the market launch of our product. Other clinics are already registering a strong interest, so we are confident that we will quickly be able to market Spherox on a broad basis with our own distribution network.”

CO.DON AG develops, produces and distributes autologous cell therapies for the minimally invasive repair of cartilage defects. The product being marketed is a cell therapy product for the minimally invasive treatment of cartilage damage in the knee joint that uses only the patient's own cartilage cells ("autologous chondrocytes"). CO.DON's method is currently used in over 200 clinics in Germany and more than 15,000 patients have already been treated. In July 2017 CO.DON received EU-wide marketing authorisation for its product, with approval for Switzerland following in March 2019. At its site in Leipzig CO.DON has built one of the largest and most modern plants for the industrial-scale production and contract manufacturing of human cells. The shares in CO.DON AG are listed on the Frankfurt Stock Exchange (ISIN: DE000A1K0227). Executive Board: Tilmann Bur.

Further information is available from



Matthias Meißner
Director Corporate Communications
Investor Relations / Public Relations
T: +49 (0)30-240352330
F: +49 (0)30-240352309